Apr. 17 at 7:06 PM
$TEM GREAT FOWARD LOOKING ARTICLE
TEM Stock To
$400?
Tempus AI has gained strong momentum following FDA approval of its upgraded Tempus Pixel platform, an AI-powered cardiac imaging system. The company is emerging as a major force in AI-driven healthcare, using a rapidly expanding data platform to advance precision medicine across oncology, cardiology, radiology, and mental health.
Revenue has grown roughly 50% on average over the past three years, with recent growth near 90% year-over-year and guidance around
$1.26 billion. Tempus benefits from a massive data advantage, with tens of millions of patient records and extensive datasets that improve AI performance and drive adoption.
With multiple revenue streams—including diagnostics, pharma partnerships, data licensing, and AI services—long-term projections suggest that if Tempus scales to tens of billions in revenue, it could support significantly higher valuations over time.
